BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 31402200)

  • 1. Phosphatidylethanolamine binding protein-4 (PEBP4) is increased in IgA nephropathy and is associated with IgA-positive B-cells in affected kidneys.
    Taylor S; Pieri K; Nanni P; Tica J; Barratt J; Didangelos A
    J Autoimmun; 2019 Dec; 105():102309. PubMed ID: 31402200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes.
    Berthelot L; Robert T; Vuiblet V; Tabary T; Braconnier A; Dramé M; Toupance O; Rieu P; Monteiro RC; Touré F
    Kidney Int; 2015 Oct; 88(4):815-22. PubMed ID: 26061544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glomerular Immunodeposits of Patients with IgA Nephropathy Are Enriched for IgG Autoantibodies Specific for Galactose-Deficient IgA1.
    Rizk DV; Saha MK; Hall S; Novak L; Brown R; Huang ZQ; Fatima H; Julian BA; Novak J
    J Am Soc Nephrol; 2019 Oct; 30(10):2017-2026. PubMed ID: 31444275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycosylation of IgA1 and pathogenesis of IgA nephropathy.
    Novak J; Julian BA; Mestecky J; Renfrow MB
    Semin Immunopathol; 2012 May; 34(3):365-82. PubMed ID: 22434325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recognition of galactose-deficient O-glycans in the hinge region of IgA1 by N-acetylgalactosamine-specific snail lectins: a comparative binding study.
    Gomes MM; Suzuki H; Brooks MT; Tomana M; Moldoveanu Z; Mestecky J; Julian BA; Novak J; Herr AB
    Biochemistry; 2010 Jul; 49(27):5671-82. PubMed ID: 20507092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-transplant immunoglobulin A deposition and nephropathy in allografts.
    Sofue T; Suzuki H; Ueda N; Kushida Y; Minamino T
    Nephrology (Carlton); 2018 Jul; 23 Suppl 2():4-9. PubMed ID: 29968406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesangial cells from patients with IgA nephropathy have increased susceptibility to galactose-deficient IgA1.
    Ebefors K; Liu P; Lassén E; Elvin J; Candemark E; Levan K; Haraldsson B; Nyström J
    BMC Nephrol; 2016 Apr; 17():40. PubMed ID: 27044423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum under-O-glycosylated IgA1 level is not correlated with glomerular IgA deposition based upon heterogeneity in the composition of immune complexes in IgA nephropathy.
    Satake K; Shimizu Y; Sasaki Y; Yanagawa H; Suzuki H; Suzuki Y; Horikoshi S; Honda S; Shibuya K; Shibuya A; Tomino Y
    BMC Nephrol; 2014 Jun; 15():89. PubMed ID: 24928472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunostaining for galactose-deficient immunoglobulin A is not specific for primary immunoglobulin A nephropathy.
    Cassol CA; Bott C; Nadasdy GM; Alberton V; Malvar A; Nagaraja HN; Nadasdy T; Rovin BH; Satoskar AA
    Nephrol Dial Transplant; 2020 Dec; 35(12):2123-2129. PubMed ID: 31369128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy.
    Myette JR; Kano T; Suzuki H; Sloan SE; Szretter KJ; Ramakrishnan B; Adari H; Deotale KD; Engler F; Shriver Z; Wollacott AM; Suzuki Y; Pereira BJG
    Kidney Int; 2019 Jul; 96(1):104-116. PubMed ID: 31027890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IgA nephropathy and Henoch-Schoenlein purpura nephritis: aberrant glycosylation of IgA1, formation of IgA1-containing immune complexes, and activation of mesangial cells.
    Novak J; Moldoveanu Z; Renfrow MB; Yanagihara T; Suzuki H; Raska M; Hall S; Brown R; Huang WQ; Goepfert A; Kilian M; Poulsen K; Tomana M; Wyatt RJ; Julian BA; Mestecky J
    Contrib Nephrol; 2007; 157():134-8. PubMed ID: 17495451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot and comparative study between pathological and serological levels of immunoglobulin and complement among three kinds of primary glomerulonephritis.
    Dong J; Peng T; Gao J; Jia X; Yan G; Wang Y
    BMC Immunol; 2018 Jun; 19(1):18. PubMed ID: 29925312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sparsentan ameliorates glomerular hypercellularity and inflammatory-gene networks induced by IgA1-IgG immune complexes in a mouse model of IgA nephropathy.
    Reily C; Moldoveanu Z; Pramparo T; Hall S; Huang ZQ; Rice T; Novak L; Komers R; Jenkinson CP; Novak J
    Am J Physiol Renal Physiol; 2024 May; 326(5):F862-F875. PubMed ID: 38511222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The landscape and diagnostic potential of T and B cell repertoire in Immunoglobulin A Nephropathy.
    Huang C; Li X; Wu J; Zhang W; Sun S; Lin L; Wang X; Li H; Wu X; Zhang P; Xu G; Wang H; Liu H; Liu Y; Chen D; Zhuo L; Li W; Yang H; Wang J; Wang L; Liu X
    J Autoimmun; 2019 Feb; 97():100-107. PubMed ID: 30385082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression.
    Maixnerova D; Ling C; Hall S; Reily C; Brown R; Neprasova M; Suchanek M; Honsova E; Zima T; Novak J; Tesar V
    PLoS One; 2019; 14(2):e0212254. PubMed ID: 30794576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89-IgA and IgG-IgA complexes: common mechanisms for distinct diseases.
    Tissandié E; Morelle W; Berthelot L; Vrtovsnik F; Daugas E; Walker F; Lebrec D; Trawalé JM; Francoz C; Durand F; Moura IC; Paradis V; Moreau R; Monteiro RC
    Kidney Int; 2011 Dec; 80(12):1352-63. PubMed ID: 21866091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IgA-containing immune complexes in the urine of IgA nephropathy patients.
    Matousovic K; Novak J; Yanagihara T; Tomana M; Moldoveanu Z; Kulhavy R; Julian BA; Konecny K; Mestecky J
    Nephrol Dial Transplant; 2006 Sep; 21(9):2478-84. PubMed ID: 16757497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy.
    Novak J; Julian BA; Tomana M; Mestecky J
    Semin Nephrol; 2008 Jan; 28(1):78-87. PubMed ID: 18222349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular signaling and production of galactose-deficient IgA1 in IgA nephropathy, an autoimmune disease.
    Reily C; Ueda H; Huang ZQ; Mestecky J; Julian BA; Willey CD; Novak J
    J Immunol Res; 2014; 2014():197548. PubMed ID: 25152896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding capacity and pathophysiological effects of IgA1 from patients with IgA nephropathy on human glomerular mesangial cells.
    Wang Y; Zhao MH; Zhang YK; Li XM; Wang HY
    Clin Exp Immunol; 2004 Apr; 136(1):168-75. PubMed ID: 15030528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.